Prévisions

L'objectif de cours moyen des analystes est de 86,58 € (+36,35 %). La médiane est de 86,58 € (+36,35 %).

Acheter
  10
Conserver
  2
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • RadNet beats Q2 forecasts and raises full-year guidance

    RadNet reported adjusted EPS of $0.29 for Q2 2026 on revenue of $622.7m, both well above consensus estimates, and posted an adjusted EBITDA quarterly record of $99.7m. Total revenue rose 25% year over year, driven by stronger demand for advanced imaging and a 56.5% increase in digital-health revenue; ARR nearly doubled to $105.5m. The company raised its full-year targets for imaging revenue, adjusted EBITDA and free cash flow. The stock rose about 6% in after-hours trading, while management highlighted accelerated adoption of AI solutions and continued wage-pressure and integration risks. » Plus sur de.investing.com


  • RadNet secures $250 million loan and lowers interest costs

    RadNet has amended its existing credit agreement and taken on an additional $250 million loan, which is being combined with the existing facility (totaling $1.2087 billion) and matures on April 18, 2031. Quarterly principal payments will rise from $2.4 million to about $3.1 million. RadNet plans to use the funds for acquisitions, organic growth, healthcare partnerships and general corporate purposes. The interest rate has been cut by 0.25 percentage points (choice of Term SOFR plus 2.00% or an alternate base rate plus 1.00%), and the terms of the revolving credit line were also improved, strengthening the company’s financial flexibility with a cash position of $455 million as of March 31, 2026. » Plus sur de.investing.com


  • DeepHealth (RadNet subsidiary) launches AI platform Reporting Pro for radiology reporting

    DeepHealth, a wholly owned subsidiary of RadNet, has made Reporting Pro commercially available — an AI-powered platform for creating radiology reports that combines speech recognition, clinical AI findings, measurements, generative AI assessments, and quality assurance in a single workflow. The solution incorporates both FDA-cleared and CE-marked AI tools, can integrate with existing PACS/RIS systems, and supports all imaging modalities. RadNet is rolling out Reporting Pro across its own network, has secured initial external customers, and plans to expand into additional countries by the end of the year. » Plus sur de.investing.com


  • Moody's cuts rating of RadNet's senior secured bank credit facilities after $200m loan

    Moody’s downgraded RadNet’s senior secured bank credit facilities from Ba3 to B1; the Corporate Family Rating remains at B1 with a stable outlook. The downgrade follows the issuance of an additional $200 million senior loan to finance acquisitions and expansion, which raises pro forma leverage from about 4.5x to around 5.0x. Moody’s cites higher fixed costs and geographic concentration as pressure points, but highlights RadNet’s strong competitive position, revenue diversification and a pro forma liquidity position of more than $600 million, and expects leverage to decline over the next 12–18 months. » Plus sur de.investing.com


  • RadNet beats revenue forecasts in Q1 2026, stock rises despite EPS miss

    RadNet reported Q1 2026 revenue of $575.63 million versus $557.64 million expected (+3.23% surprise) with EPS of $-0.28 (forecast -$0.15). Revenue rose 22.1% year over year, adjusted EBITDA increased 36.3%, and days sales outstanding (DSO) were 29.5 days. The stock climbed 8.95% in premarket trading to $63.40 as investors reacted positively to revenue growth, digital health initiatives and acquisition contributions. RadNet maintains an upbeat outlook with FY 2026 guidance of $0.63 EPS and expected revenues of $2.45 billion. » Plus sur de.investing.com

Données financières

Au dernier trimestre, RadNet a réalisé un chiffre d'affaires de 563,49 M € et un bénéfice net de 3,67 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 563,49 M 26,47 %
Bénéfice brut 75,81 M 22,74 %
Bénéfice net 3,67 M 20,57 %
EBITDA 84,05 M 27,39 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
5 Md €
Nombre d'actions
78,77 M
Plus haut/bas sur 52 semaines
78,23 € - 46,31 €
Dividendes Non
Bêta
1,40
Ratio P/E
-242,22
Ratio PEG
3,65
Ratio P/B
4,84
Ratio P/S
2,30

Profil de l'entreprise

RadNet, Inc., ainsi que ses filiales, fournit des services d'imagerie diagnostique ambulatoire aux États-Unis. Ses services comprennent l'imagerie par résonance magnétique, la tomodensitométrie, la tomographie par émission de positons, la médecine nucléaire, la mammographie, l'échographie, la radiologie diagnostique, la fluoroscopie et d'autres actes connexes, ainsi que des services d'imagerie multimodalité. La société développe et commercialise également des systèmes informatisés destinés au secteur de l'imagerie diagnostique, notamment des systèmes d'archivage et de communication d'images (PACS) et des services associés ; elle développe et déploie en outre des suites d'intelligence artificielle destinées à améliorer l'interprétation des images par les radiologues dans le domaine de la mammographie, ainsi que des solutions d'IA pour le cancer du poumon et de la prostate. Au 31 décembre 2021, elle possédait et gérait 347 centres en Arizona, en Californie, dans le Delaware, en Floride, dans le Maryland, dans le New Jersey et dans l'État de New York. La société a été fondée en 1981 et son siège social est situé à Los Angeles, en Californie.

Nom
RadNet
PDG
Howard G. Berger
Siège social Los Angeles, ca
États-Unis
Site web
Secteur
Santé
Industrie
Équipements et fournitures médicaux
Introduction en bourse
10/12/2021
Employés 9 060

Symboles boursiers

Bourse Symbole
NASDAQ
RDNT
Frankfurt
PQIA.F
Düsseldorf
PQIA.DU
SIX
PQIA.SW
🍪

Parqet  utilise des cookies. En savoir plus